Company Profile
Sansure Biotech Inc. is a China-based manufacturer of molecular diagnostic reagents and instruments, headquartered in Changsha, Hunan. Founded on 23 April 2008 by Dr. Dai Lizhong, the company was listed on the Shanghai Stock Exchange STAR Market (688289) in August 2020. Sansure employs 2,346 people and operates as one of China's leading in-vitro diagnostic (IVD) providers, offering over 1,000 diagnostic products and 2,200 testing services.
Core Products ＆ Technologies
Infectious Disease Molecular Diagnostics
• Viral Hepatitis Series: Nucleic acid test kits for hepatitis B, C, and D virus quantification and genotyping
• Respiratory Pathogen Panels: Multiplex PCR assays covering 6/7 pathogens for influenza, RSV, and atypical pneumonia; 20+ respiratory products cleared
• Blood Screening Series: NAT assays for HIV, HBV, and HCV in blood donations and transfusion safety
• Paediatric Infection Series: Enterovirus, rotavirus, and adenovirus detection kits for childhood infectious diseases
• Reproductive ＆ Genetic Testing: HPV genotyping, sexually transmitted infection panels, and prenatal screening assays
Automated Instrument Platforms
• Portable Fully-Automated Nucleic Acid Extraction ＆ Amplification Systems: Point-of-care molecular diagnostic instruments integrating sample processing, extraction, and real-time PCR detection
• High-Throughput PCR Systems: Laboratory-scale automated nucleic acid extraction workstations for batch processing
• Gene Sequencing Platforms: SansureSeq1000 (high-throughput), FASTASeq300Dx (desktop), and FASTASeqS (rapid) forming a complete sequencing instrument matrix
AI-Enabled Diagnostics ＆ Services
• SUREXEVO Molecular POCT: Global-first AI-integrated molecular point-of-care testing system shortlisted for national AI medical device innovation program
• Sansure Gene Laboratory: Centralized molecular diagnostic testing services for hospitals and clinics
• Intelligent Diagnostic Software: AI-driven result interpretation and laboratory information management systems
Market Position ＆ Certifications
Sansure holds a leading position in China's molecular diagnostics market, competing with Roche Diagnostics, Danaher (Cepheid), Abbott, BGI Genomics, and Daan Diagnostic. Key strengths include:
• 17+ years of gene technology innovation heritage
• Comprehensive portfolio: One of China's most complete molecular diagnostic product lines with 1,000+ assays and 2,200+ services
• Regulatory compliance: NMPA Class III registrations, CE marked exports, and WHO prequalification for select products; 1,800+ domestic and international regulatory approvals cumulatively
• National program participation: Key supplier for China's infectious disease prevention and control programs; undertook national 13th and 14th Five-Year major science and technology projects
• Global reach: Products and solutions serving 160+ countries and regions including France, USA, Germany, Spain, Brazil, Indonesia, Thailand, and Saudi Arabia
Corporate Timeline
2008 — Founded in Changsha by Dr. Dai Lizhong, returning from Gen-Probe (USA)
2015 — Achieved breakthrough in high-precision magnetic bead nucleic acid extraction technology
2020 — Listed on Shanghai STAR Market (688289); launched SARS-CoV-2 RT-PCR kit within days of pandemic onset
2023 — Established Sansure Ansys joint venture for immunodiagnostics and chemiluminescence expansion
2025 — Acquired Zhongshan Haiji (renamed Sansure Haiji) entering growth hormone therapy; increased stake in GeneMind (gene sequencing) to 15.55%; four new products received NMPA registration; R＆D investment reached RMB 310 million (19% of revenue)
2026 — Acquired majority stake in German inno-train Diagnostik GmbH (HLA and blood molecular diagnostics); Sansure Haiji received NMPA clinical trial approval for growth hormone ISS indication; Hunan Jin Furong Sansure Industry Fund completed first close of RMB 820 million; disclosed 2025 annual report with revenue of RMB 1.642 billion
Target Markets ＆ Applications
• Clinical Laboratory Diagnostics: PCR-based pathogen detection for hospital laboratories and reference centers
• Blood Transfusion Safety: Nucleic acid screening of donated blood for transfusion-transmitted infections
• Point-of-Care Testing: Portable automated systems for emergency and resource-limited settings
• Epidemic Preparedness: Rapid assay development for emerging infectious diseases and pandemic response
• Preventive Healthcare: HPV screening and reproductive health monitoring for population-level disease prevention
• Genetic Testing ＆ Sequencing: NGS-based solutions for oncology, hereditary disease, and pharmacogenomics
Contact Information
Global Headquarters
Address: No. 680 Lusong Road, Changsha High-Tech Industrial Development Zone, Changsha, Hunan 410205, China
Phone: +86 731 8888 3176
Fax: +86 731 8422 3503
Email: dmb@sansure.com.cn
Website: www.sansure.com.cn
